Wegovy taper off schedule: what the evidence and guidance actually say

What the STEP 1 extension study found when participants stopped semaglutide

The clearest evidence on stopping Wegovy comes from the STEP 1 withdrawal extension, published in the New England Journal of Medicine. Adults who had lost an average of around 15% of their body weight on 2.4 mg semaglutide were followed after treatment ended. Within 52 weeks of stopping, they had regained roughly two-thirds of the weight they had lost, and cardiometabolic markers moved in parallel. Hunger returned relatively quickly for many participants. This is not a failure of willpower. Semaglutide's effects on appetite signalling are pharmacological; once the drug clears, those signals can return to baseline.

The half-life of semaglutide is approximately one week, which means the drug is still biologically active for several weeks after the last injection. That gradual pharmacological wind-down is sometimes described as a natural taper, though it is not the same as a clinician-supervised step-down in dose, and whether you need to taper off Wegovy at all is a question worth working through before your final injection. Understanding this pharmacokinetics point helps explain why stopping from 2.4 mg feels different from stopping from 0.25 mg: there is more to clear.

For the full story on what the Wegovy dosing schedule involves from start to maintenance, that page covers the titration pathway in detail.

Does the SmPC or NHS guidance specify a formal taper-off protocol?

The short answer is no. The Wegovy SmPC (the authoritative prescribing document held on the Electronic Medicines Compendium (eMC)) does not lay out a mandatory step-down schedule. It advises that if a patient does not achieve meaningful weight loss by a defined point at the highest tolerated dose, continuing treatment should be reconsidered, but it does not prescribe a specific tapering ladder for patients who choose or need to stop.

The NHS England weight-management injections guidance reinforces that treatment decisions (including stopping) should involve the prescribing clinician and, where possible, the wider care team. The emphasis is on planning: what happens to diet and activity support when the medicine stops?

Some prescribers do choose to step patients back through lower doses (for example, from 2.4 mg to 1.7 mg to 1.0 mg over several weeks) to reduce any rebound in appetite, but this is clinical practice rather than a regulatory requirement. Whether that approach suits you depends on your response to the medicine, your reasons for stopping, and your longer-term plan. Those questions sit with your prescriber, not a standard protocol.

If you are weighing up whether stopping is even necessary, the page on whether you have to taper off Wegovy covers that question specifically.

Weight regain after stopping: the practical picture

Planning for what follows Wegovy matters more than the mechanics of the final few injections. The STEP 1 data are unambiguous: without continued treatment or sustained behavioural support, weight tends to return. This reflects the underlying biology of obesity, not a one-off event. The NHS medicines page for semaglutide notes that it should be used alongside a reduced-calorie diet and increased physical activity, and those elements become load-bearing once the pharmacological appetite suppression is removed.

Practically, the weeks after stopping are worth treating as an active transition. Protein intake, regular meals and whatever movement habits you have built tend to do more work in this period. Clinicians often recommend booking a follow-up within four to six weeks of the final dose rather than waiting to see how things go.

Cost sometimes drives the stopping decision. The context around Wegovy pricing in the UK is worth reading if that is a factor, because the calculation changes depending on what dose you are on and how long you have been at maintenance.

For a detailed look at how to approach the process practically, see the guide to how to taper off Wegovy.

When and how to involve your prescriber, and what comes next

Stopping Wegovy is a clinical decision. The prescriber who manages your semaglutide treatment should know before you stop, not after. There are several scenarios where the timing and method matter more: if you are stopping because of side effects, an underlying condition change, planned surgery (surgical teams need to know you are or have been on a GLP-1 medicine), or pregnancy planning. In those cases, a brief conversation can make a real difference to what happens next.

At nume, every repeat order is reviewed by a real clinician before it is processed. That same clinical relationship is the right place to raise questions about stopping, stepping down, or switching. A named prescriber reads your case (not a form routed to a queue) and can advise on whether a gradual step-down makes sense for you specifically. You can start that conversation by checking your eligibility below, or if you are already a patient, reach the clinical team through the contact page.

If you are not yet on treatment and are considering Wegovy for the first time, the weight-loss treatment overview is a good starting point for understanding what is available and licensed in the UK.